BCTX
BriaCell Therapeutics Corp. NASDAQ Listed Mar 14, 2012$3.06
+3.03%
vs $2.97
Mkt Cap $5.8M
52w Low $2.74
1.1% of range
52w High $31.10
50d MA $3.56
200d MA $6.61
P/E (TTM)
—
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.0x
ROE
721.2%
P/FCF
-0.1x
RSI (14)
49.00
ATR (14)
$0.21
Beta
1.63
50d MA
$3.56
200d MA
$6.61
Avg Volume
264.2K
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Bellevue Centre · West Vancouver, BC V7T 2X1 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -4.84 | -2.58 | +46.7% | 3.81 | +0.3% | +13.9% | -0.9% | -1.9% | +3.1% | +4.6% | — |
| Dec 11, 2025 | AMC | — | -4.35 | — | 10.31 | -0.1% | -7.5% | -5.9% | -3.1% | +0.3% | +3.2% | — |
| Oct 27, 2025 | AMC | -12.11 | -10.49 | +13.4% | 13.42 | +0.1% | -0.6% | -6.7% | -8.7% | -3.2% | -9.1% | — |
| Jun 16, 2025 | AMC | -17.60 | -16.40 | +6.8% | 31.60 | -1.6% | -1.3% | +0.0% | -1.9% | -5.9% | +3.1% | — |
| Mar 12, 2025 | AMC | -19.40 | -23.30 | -20.1% | 36.50 | -2.7% | -5.5% | +11.3% | +6.0% | -4.7% | +10.1% | — |
| Dec 16, 2024 | AMC | -0.30 | -32.98 | -9999.0% | 91.22 | -4.5% | +6.2% | -4.6% | -5.0% | -4.1% | -5.7% | — |
| Jul 31, 2024 | AMC | — | -0.73 | — | 112.88 | -1.7% | -3.6% | -3.5% | -9.6% | -3.6% | -1.7% | — |
| Jun 14, 2024 | AMC | -82.46 | 16.49 | +120.0% | 213.00 | +0.0% | +4.2% | -9.5% | -4.5% | -6.6% | -6.3% | — |
| Mar 18, 2024 | AMC | -29.99 | -106.45 | -255.0% | 435.00 | -3.1% | -6.6% | -17.3% | +1.8% | +10.5% | +13.1% | — |
| Dec 14, 2023 | AMC | -26.99 | -74.96 | -177.7% | 630.00 | +2.9% | -1.7% | +0.0% | -4.6% | +3.6% | -1.7% | — |
| Jul 31, 2023 | AMC | — | -1.70 | — | 1003.50 | -2.8% | +1.6% | +1.6% | -1.2% | -2.5% | -0.9% | — |
| Jun 14, 2023 | AMC | -53.97 | -47.98 | +11.1% | 889.50 | -2.0% | +2.2% | -0.5% | -4.6% | -0.6% | +4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.21 | $8.30 | +1.1% | -7.4% | -3.9% | +6.4% | +9.0% | -2.6% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.90 | $41.50 | -1.0% | +27.7% | +1.5% | +11.0% | -13.8% | -3.8% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.20 | $72.40 | +44.2% | +0.4% | -18.7% | +9.3% | -9.6% | -7.9% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $165.00 | $102.27 | -38.0% | -39.9% | -0.2% | -7.9% | +6.2% | -4.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $166.50 | $159.00 | -4.5% | +4.5% | -10.3% | -2.9% | -5.2% | +24.3% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $151.50 | $144.17 | -4.8% | -5.0% | +2.5% | +8.7% | +0.9% | -14.4% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $78.50 | $81.00 | +3.2% | +15.1% | +7.7% | +5.1% | -7.3% | +20.2% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.93 | $289.50 | +211.5% | +3.3% | -1.6% | -11.0% | -11.9% | -4.8% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $229.50 | $232.50 | +1.3% | -8.5% | +4.3% | -1.4% | -3.5% | +0.0% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $214.50 | $220.50 | +2.8% | +0.7% | -4.9% | +12.4% | +3.2% | +6.3% |
No insider trades available.
8-K · 7.01
! Medium
BriaCell Therapeutics Corp. -- 8-K 7.01: Regulation FD Disclosure
Jun 26
8-K · 3.02
!! High
BriaCell Therapeutics Corp. -- 8-K 3.02: Unregistered Securities Offering
Jun 3
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
BioCorRx's disclosure of six-month financial results suggests investors should monitor operational progress and cash burn rate, as biotech companies typically face near-term funding needs and development milestones.
Mar 31
8-K
Briacell Therapeutics Corp. Common Shares -- 8-K Filing
Briacell Therapeutics successfully held its shareholder meeting and elected its board of directors, with voting results showing strong investor support for the company's leadership going forward.
Mar 9
8-K · 8.01
!! High
Briacell Therapeutics Corp. Common Shares -- 8-K 8.01: Material Event / Announcement
Briacell Therapeutics sold its Soluble CD80 cancer therapy license to subsidiary BriaPro for 23.97 million shares, raising its ownership stake to approximately 78% and consolidating control of the asset.
Feb 20
Institutional (13F) — Top 11
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Iridian Asset Management Llc/ct | 65,000 | $272K | New | Mar 2026 |
| 2 | Luminarx Capital Management Lp | 15,000 | $63K | New | Mar 2026 |
| 3 | Morgan Stanley | 7,002 | $50K | Added | Dec 2025 |
| 4 | Ubs Group Ag | 11,541 | $48K | Added | Mar 2026 |
| 5 | Flagship Harbor Advisors, Llc | 4,000 | $28K | New | Dec 2025 |
| 6 | Federation Des Caisses Desjardins Du Quebec | 455 | $2K | Reduced | Mar 2026 |
| 7 | Td Waterhouse Canada Inc. | 19 | $78 | — | Mar 2026 |
| 8 | Hhm Wealth Advisors, Llc | 6 | $26 | — | Mar 2026 |
| 9 | Wells Fargo & Company/mn | 1 | $4 | New | Mar 2026 |
| 10 | Fny Investment Advisers, Llc | 10 | — | — | Mar 2026 |
| 11 | Royal Bank Of Canada | 100 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$5.8M
Enterprise Value
-$18.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
0.24x
P/S
—
P/FCF
-0.15x
EV/EBITDA
—
Shares Out
1.9M
Financials (TTM)
Revenue
$0
Net Income
-$37.1M
EBITDA
-$38.6M
Free Cash Flow
-$39.1M
Op Cash Flow
-$39.1M
EPS Basic
$-86.25
EPS Diluted
$-13.84
EPS Forward
$-11.45
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$29.8M
Total Liab.
$5.9M
Total Equity
$23.8M
Cash
$24.6M
LT Debt
$0
Book Value/Sh
$12.65
Debt/Equity
0.00x
Current Ratio
5.01
Quick Ratio
5.01
Returns & Growth
ROE
721.2%
ROA
-81.1%
ROIC
-155.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
-44.5%
Price Returns
2W
-10.1%
1M
-12.9%
3M
-4.7%
6M
-62.6%
12M
-89.4%
Technicals
52W High
$31.10
52W Low
$2.74
50d MA
$3.56
200d MA
$6.61
RSI (14)
49.00
ATR (14)
$0.21
Beta
1.63
Avg Volume
264K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 8:59pm
· Source: financialmodelingprep.com